𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I clinical trial of human recombinant beta interferon in relapsing-remitting multiple sclerosis

✍ Scribed by J.I. Greenstein; R.L. Knobler; K.P. Johnson; S.G. Marcus; H.S. Panitch; F.D. Lublin; R.M. Hassett; J.R. Wilson; A.M. Russick; A.S. Haley; S.V. Grant

Book ID
119106964
Publisher
Elsevier Science
Year
1987
Tongue
English
Weight
35 KB
Volume
16
Category
Article
ISSN
0165-5728

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Rituximab in relapsing-remitting multipl
Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial
✍ Amit Bar-Or; Peter A. J. Calabresi; Douglas Arnold; Clyde Markowitz; Stuart Shaf πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 171 KB

## Abstract We evaluated the safety, tolerability, pharmacodynamics, and activity of B‐cell depletion with rituximab in patients with relapsing‐remitting multiple sclerosis, receiving two courses of rituximab 6 months apart, and followed for a total of 72 weeks. No serious adverse events were noted